Arbutus Biopharma appoints Mike McElhaugh as COO effective Nov 1, 2022; salary to $460,000

Arbutus Biopharma Corp

Mike McElhaugh promoted from Chief Business Officer to Chief Operating Officer, effective November 1, 2022.
Annual base salary increased to $460,000 under third amendment to existing employment agreement.
McElhaugh has been with Arbutus since 2014 and was a co-founder of OnCore Biopharma acquired by Arbutus in 2015.
No other changes to employment terms; no family relationships or transactions requiring disclosure.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Mike McElhaugh

Chief Operating Officer

ABUS · Arbutus Biopharma Corp

Effective: 2022-11-01
Filed: October 24, 2022, 7:59 PM ET

On October 18, 2022, the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) appointed Mike McElhaugh, age 48, as the Company’s Chief Operating Officer, effective as of November 1, 2022

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Mike McElhaugh was appointed as Chief Operating Officer at Arbutus Biopharma Corp.

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

On October 18, 2022, the Board of Directors (the “Board”) of Arbutus Biopharma Corporation (the “Company”) appointed Mike McElhaugh, age 48, as the Company’s Chief Operating Officer, effective as of November 1, 2022

View on SEC.gov

Arbutus Biopharma Corp filing history →

Source: SEC EDGAR

accession 0001447028-22-000051

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.